11/19
10:14 am
bhvn
XVIVO Wins Two Davey Awards: A Gold and a Silver for Two Animation Programs
Low
Report
XVIVO Wins Two Davey Awards: A Gold and a Silver for Two Animation Programs
11/14
08:15 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
11/13
01:46 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $55.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at TD Cowen from $55.00 to $75.00. They now have a "buy" rating on the stock.
11/13
10:08 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $66.00. They now have an "outperform" rating on the stock.
Medium
Report
Biohaven Ltd. (NYSE: BHVN) had its price target lowered by analysts at Royal Bank of Canada from $68.00 to $66.00. They now have an "outperform" rating on the stock.
11/13
02:25 am
bhvn
Biohaven Non-GAAP EPS of -$1.74 misses by $0.24 Nov. 13, 2024 2:24 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
Medium
Report
Biohaven Non-GAAP EPS of -$1.74 misses by $0.24 Nov. 13, 2024 2:24 AM ET By: Meghavi Singh , SA News Editor [Seeking Alpha]
11/12
04:05 pm
bhvn
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
Low
Report
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
10/23
12:32 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/4
09:54 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/4
02:27 am
bhvn
AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA [Yahoo! Finance]
Low
Report
AbbVie's atogepant set to reach projected worth of $766m in 2026 after accepted NDA from FDA [Yahoo! Finance]
10/3
12:23 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $68.00. They now have an "overweight" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $68.00. They now have an "overweight" rating on the stock.
10/3
08:49 am
bhvn
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock [Yahoo! Finance]
Medium
Report
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock [Yahoo! Finance]
10/2
04:05 pm
bhvn
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Low
Report
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
10/1
06:55 am
bhvn
Biohaven prices $250M share offering [Seeking Alpha]
Low
Report
Biohaven prices $250M share offering [Seeking Alpha]
10/1
06:00 am
bhvn
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
Low
Report
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
9/30
04:23 pm
bhvn
Biohaven proposed public offering of common shares [Seeking Alpha]
Low
Report
Biohaven proposed public offering of common shares [Seeking Alpha]
9/30
04:05 pm
bhvn
Biohaven Announces Proposed Public Offering of Common Shares
Low
Report
Biohaven Announces Proposed Public Offering of Common Shares
9/30
07:30 am
bhvn
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
Low
Report
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
9/24
01:13 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Bank of America Co. from $52.00 to $62.00. They now have a "buy" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Bank of America Co. from $52.00 to $62.00. They now have a "buy" rating on the stock.
9/24
01:13 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Sanford C. Bernstein from $55.00 to $66.00. They now have an "outperform" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Sanford C. Bernstein from $55.00 to $66.00. They now have an "outperform" rating on the stock.
9/24
12:29 pm
bhvn
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal [Yahoo! Finance]
Low
Report
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal [Yahoo! Finance]
9/24
09:14 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/24
09:14 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Royal Bank of Canada from $59.00 to $68.00. They now have an "outperform" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Royal Bank of Canada from $59.00 to $68.00. They now have an "outperform" rating on the stock.
9/24
08:09 am
bhvn
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.
9/23
07:06 pm
bhvn
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Leerink Partners from $55.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Leerink Partners from $55.00 to $60.00. They now have an "outperform" rating on the stock.
9/23
02:21 pm
bhvn
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug [Yahoo! Finance]
Low
Report
Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug [Yahoo! Finance]